Sime Armoyan Sells 15,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of C$5.95, for a total transaction of C$89,250.00.

Sime Armoyan also recently made the following trade(s):

• On Thursday, April 11th, Sime Armoyan sold 10,900 shares of Knight Therapeutics stock. The stock was sold at an average price of C$5.95, for a total transaction of C$64,855.00.
• On Monday, April 1st, Sime Armoyan bought 6,200 shares of Knight Therapeutics stock. The stock was purchased at an average price of C$5.25 per share, with a total value of C$32,550.00.
• On Monday, March 25th, Sime Armoyan purchased 351,000 shares of Knight Therapeutics stock. The stock was bought at an average cost of C$5.25 per share, with a total value of C$1,842,750.00.

Knight Therapeutics Price Performance

TSE GUD opened at C$6.10 on Friday. The firm has a market capitalization of C$617.14 million, a price-to-earnings ratio of -38.13, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.49. The company has a 50 day simple moving average of C$5.57 and a 200-day simple moving average of C$5.37. The company has a debt-to-equity ratio of 9.25, a current ratio of 3.20 and a quick ratio of 1.79. Knight Therapeutics Inc. has a 52-week low of C$4.35 and a 52-week high of C$6.17.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, March 21st. The company reported C($0.03) earnings per share for the quarter, missing the consensus estimate of C$0.02 by C($0.05). The business had revenue of C$74.20 million for the quarter, compared to the consensus estimate of C$78.37 million. Knight Therapeutics had a negative net margin of 5.13% and a negative return on equity of 2.14%. Equities research analysts predict that Knight Therapeutics Inc. will post 0.0602815 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on GUD shares. Raymond James increased their price target on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an “outperform” rating in a research report on Wednesday, March 6th. Royal Bank of Canada increased their price target on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an “outperform” rating in a research report on Friday, March 22nd. Finally, Stifel Nicolaus increased their price target on shares of Knight Therapeutics from C$5.25 to C$5.40 and gave the stock a “hold” rating in a research report on Wednesday, May 1st.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.